Literature DB >> 25801338

Liver injury in patients with DRESS: A clinical study of 72 cases.

I-Chun Lin1, Hung-Chih Yang2, Carol Strong3, Che-Wen Yang1, Yung-Tsu Cho1, Kai-Lung Chen1, Chia-Yu Chu4.   

Abstract

BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a syndrome involving multiple systems. Liver injury is the most common visceral manifestation.
OBJECTIVE: The purpose of this study was to investigate the types of liver injury and factors associated with DRESS.
METHODS: A retrospective cohort study was conducted in Taiwan using a DRESS database compiled from December 2000 to March 2013.
RESULTS: Seventy-two cases were included in this study. Among them, 62 (86.1%) cases involved liver injury, 6 of which (9.7%) were liver injury before skin presentation. The distribution of liver injury patterns at initial presentation was 23 cholestatic type (37.1%), 17 mixed type (27.4%), and 12 hepatocellular type (19.4%). Patients with hepatocellular-type injuries were younger, with a median age of 31.5 (P = .044). Individuals with liver function results more than 10 times the upper limit were more likely to have fever (P = .026), took more time to recover, and had fewer eosinophils in the dermis (P = .002). LIMITATIONS: The study was a retrospective cohort study with limited cases.
CONCLUSIONS: Liver injury is common in DRESS and frequently associated with atypical lymphocytosis. The cholestatic type is the most common type. Patients with cholestatic-type injuries were older and more frequently had interface changes in skin pathology.
Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  drug eruption; drug reaction with eosinophilia and systemic symptoms; drug-induced hypersensitivity syndrome; interface change; liver injury

Mesh:

Year:  2015        PMID: 25801338     DOI: 10.1016/j.jaad.2015.02.1130

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  8 in total

Review 1.  Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.

Authors:  Antonio Segovia-Zafra; Daniel E Di Zeo-Sánchez; Carlos López-Gómez; Zeus Pérez-Valdés; Eduardo García-Fuentes; Raúl J Andrade; M Isabel Lucena; Marina Villanueva-Paz
Journal:  Acta Pharm Sin B       Date:  2021-11-18       Impact factor: 11.413

Review 2.  Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)-Readdressing the DReSS.

Authors:  Hannah Stirton; Neil H Shear; Roni P Dodiuk-Gad
Journal:  Biomedicines       Date:  2022-04-26

Review 3.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist.

Authors:  Marwan H Adwan
Journal:  Curr Rheumatol Rep       Date:  2017-01       Impact factor: 4.686

Review 4.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System.

Authors:  Yung-Tsu Cho; Che-Wen Yang; Chia-Yu Chu
Journal:  Int J Mol Sci       Date:  2017-06-09       Impact factor: 5.923

Review 5.  Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions.

Authors:  Mari Orime
Journal:  J Immunol Res       Date:  2017-10-31       Impact factor: 4.818

6.  When Autoimmunity 'DRESSes up': A Case after Certolizumab Therapy.

Authors:  Benedetta Marigliano; Federico Rosa; Mattia Internullo; Luigi Scuro; Andrea Tavanti; Lucia Rita Del Vecchio; Francesco Paolo Romagno; Maria Barbara Schito; Federica Pace; Giovanni Maria Colombo; Emanuele Guglielmelli
Journal:  Eur J Case Rep Intern Med       Date:  2022-07-14

7.  Drug rash with eosinophilia and systemic symptoms syndrome masquerading as a lymphoproliferative disorder in a young adult on immunosuppressive therapy for rheumatoid arthritis: a case report.

Authors:  Elise Hyser
Journal:  J Med Case Rep       Date:  2022-09-05

Review 8.  Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature.

Authors:  Philip Sarges; Joshua M Steinberg; James H Lewis
Journal:  Drug Saf       Date:  2016-09       Impact factor: 5.228

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.